Relievant Medsystems (Redwood City, CA) a clinical-stage medical device company focused on a device for radio frequency nerve ablation for chronic axial low back pain, closed a $30M Series D financing. Participants include New Enterprise Associates, Morgenthaler Ventures, Emergent Medical Partners, Canaan Partners and Onset Ventures.

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.

Roka BioScience (Warren, NJ) a development-stage diagnostic company focused on molecular assays for monitoring food safety applications and biopharmaceutical manufacturing, closed a $27.5M Series D financing. Participants include Aisling Capital, OrbiMed, New Enterprise Associates and TPG Biotech.

Apnex Medical (St Paul, MN) a clinical-stage medical device company focused on implantable treatments for sleep apnea, closed a $20M Series C financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.

Dermira (Redwood City, CA) a clinical-stage pharmaceutical company focused on topical treatments and light therapy for acne and inflammatory skin disease, closed a $42M Series A financing. Participants include Bay City Capital, New Enterprise Associates and Canaan Partners.

CV Ingenuity (Palo Alto, CA) a development-stage medical device company focused on vascular obstructions, closed a $16M Series B financing. Participants include New Enterprise Associates, BioStar Ventures, Synergy Ventures and Western Technology.

PatientKeeper (Waltham, MA) a commercial-stage provider of integrated physician information systems for improving patient care and physician workflow, closed a $6M Series J financing. Participants include Flybridge Capital Partners, New Enterprise Associates and Whitney & Co.

Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Tesaro (Boston, MA) a clinical-stage biopharmaceutical focused on chemotherapy induced nausea and non-small cell lung cancer, closed a $101M Series B financing. Participants include New Enterprise Associates, InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Capital Management and Leerink Swann.

VertiFlex (San Clamente, CA) a clinical-stage medical device company focused on percutaneous and motion preserving spinal surgery technologies, closed a $14M Series E financing. Participants include New Enterprise Associates, Aberdare Ventures, Alta Partners and Thomas, McNerney & Partners.

BridgePoint Medical (Minneapolis, MN) a clinical-stage medical device company focused on interventional cardiology for access to and treatment of chronic total occlusions, closed a $9.1M Series C financing. Participants include New Enterprise Associates, Polaris Venture Partners and Foundation Medical Partners.